MoonLake Immunotherapeuti... (MLTX)
| Bid | 38.41 |
| Market Cap | 2.52B |
| Revenue (ttm) | 102.19K |
| Net Income (ttm) | -119.34M |
| EPS (ttm) | -1.89 |
| PE Ratio (ttm) | -21.1 |
| Forward PE | -17.94 |
| Analyst | Buy |
| Ask | 41.14 |
| Volume | 388,414 |
| Avg. Volume (20D) | 428,368 |
| Open | 39.67 |
| Previous Close | 39.84 |
| Day's Range | 38.51 - 40.09 |
| 52-Week Range | 36.52 - 58.26 |
| Beta | 1.30 |
About MLTX
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered...
Analyst Forecast
According to 8 analyst ratings, the average rating for MLTX stock is "Buy." The 12-month stock price forecast is $73, which is an increase of 83.05% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced UponMoonLake Immunotherapeutics is set to release results from both the phase 3 VELA-1 and VELA-2 studies using sonelokimab to target moderate-to-severe Hidradenitis Suppurativa patients in mid-2025. The ...